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Abstract Drug delivery to the mucus covered mucosae is fraught with difficulties and 
many different approaches have been developed to permeate the mucus barrier.  Generally 
by modifying the delivery system to avoid interaction with the mucus.  These modifications 
are reviewed here in terms of efficacy and safety.  These are particular problems for oral 
delivery the pharmaceutical industry’s favoured route for drug administration.  For effective 
delivery through the gastrointestinal tract a drug must pass through three barriers in 
sufficient amounts to yield a biological effect.  These barriers are the digestive barrier in the 
lumen, the mucus barrier, and the epithelial barrier.   
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Other approaches involve mucolytic agents added with or prior to the delivery system or 
agents regulating mucus production and are reviewed here.  In terms of safety, a key 
property of a mucus modulating delivery system is that it must not damage the protective 
function of the mucus layer. 
Keywords Mucus; Toxicity; Efficacy; Drug Delivery; Modelling; Barrier Properties; 
Permeation 
 
1Abbreviations 
  
                                                          
chitosan (C) 
cowpea chlorotic mottle virus (CCMV) 
cowpea mosaic virus (CPMV) 
cystic fibrosis (CF) 
long chain (LC) 
medium chain (MC)  
N-acetylcysteine (NAC) 
no lipids (NL) 
poly(lactic-co-glycolic acid) (PLGA) 
periciliary layer (PCL) 
6 phosphoglucuronic acid (PGA) 
polyacrylic acid (PAA) 
polyethylene glycol (PEG) 
polyethylene imine (PEI) 
porcine small intestinal mucus (PSIM) 
pulsed-gradient spin-echo NMR (PGSE-NMR) 
self-emulsifying drug delivery systems (SEDDS) 
self-nanoemulsifying drug delivery systems (SNEDDS) 
small angle neutron scattering (SANS) 
spin-echo SANS (SESANS) 
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1. Introduction 
The effective delivery of therapeutic agents to epithelial cells of mucus secreting mucosa 
and/ or the circulation beyond is hampered by the mucus layer which is designed to trap 
particles. These are then removed as the mucus layer is turned over. In terms of designing 
an effective system to overcome the mucus barrier we must first understand the ‘enemy’. 
That involves understanding mucus structure and composition and its rate of turnover. If 
mucus turnover is faster than the drug carrier can penetrate the mucus layer then none will 
reach the epithelium. In terms of drug delivery the mucus covered epitheliums include the 
airways both upper and lower, the gastrointestinal tract excluding the mouth and the 
oesophagus which do not have an adherent mucus layer and are squamous rather than 
columnar epithelium [1]. Also considered as drug delivery targets are the mucus covered 
epithelium of cervico-vaginal tract and the ocular epithelium [2-5]. Mucus is 95% water and 
the gel forming constituent is the glycoprotein mucin [6]. IgA is actively secreted along with 
the mucin. The other components found in mucus result from shed cells e.g. DNA, actin and 
lipid. Particularly in the terminal ileum and the colon, microbial cell products contaminate 
the mucus. The makeup of mucus can be further altered in diseased states e.g. cystic 
fibrosis, with products from inflammatory cells leading to an increase of non-mucin 
components. Mucus gels once formed cannot be diluted out, but isolated gels will 
eventually be dissolved due to the action of endogenous degradative enzymes if these are 
not effectively inhibited [6]. Mucins consist of 3 groups; gel forming secreted, soluble 
secreted and membrane bound. Their structures are described in detail elsewhere [7, 8]. 
The gelling mucins consist of a highly glycosylated protein core with up to 90% of the weight 
being carbohydrate. These mucins form polymeric structures maintained by disulphide 
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bridges. The C and N terminals and bare or sparsely glycosylated regions of the protein core 
are open to proteolytic attack. Cleavage at these points will destroy the polymeric structure 
leading to solubilisation of the gel (Figure 1).  
 
 
 
 
 
Figure 1  Mucin Polymeric Structure with variable number tandem repeats (VNTR)  
The airways have a mucus barrier consisting of two layers; a layer close to the cells called 
the periciliary layer (PCL), in which the cilia beat and a mucus gel layer on top of the cilia. 
The PCL does not contain gel forming mucins but does contain membrane bound mucins 
expressed on the cilia surface and the epithelial cell apical surfaces. The identification of 
keratin sulphate (a glycosaminoglycan) in the PLC shows it is not simply a low viscosity fluid 
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[9, 10]. The reported pore sizes for these two layers are ~200nm for the mucus gel and 
between 6 and 40nm for the PCL [9]. Consequently if the drugs are to be delivered all the 
way to the cell surface then they would need to be in very small particles or in particles that 
release their cargo into the PCL after penetrating the gel layer. 
 
Mucus in the GI tract is a bilayer, with a luminal layer which is shear compliant on the 
surface which overlies a shear resistant layer [11, 12]. There is some confusion as to 
clearance rates of these two mucus layers in the literature. It is common to read in reviews 
on mucus properties and drug delivery statements like; the non-adherent layer (which 
equates to the shear compliant layer) is rapidly transported or is rapidly cleared, whereas 
the underlying adherent (shear resistant) layer has a much slower clearance rate. Implying 
that drug delivery systems trapped in the upper layer will have short residency times. It is 
important to note that the shear compliant gel becomes a viscous liquid when put under 
low levels of shear but once the shear is removed it returns to a gel [11]. Therefore the drug 
delivery particles trapped in this layer would only be cleared quickly when shear is 
continuous i.e. in the fed state but not when shear is reduced in the fasting state. There is 
however a paucity of data on GI mucus clearance particularly considering the two layers.   
 
In the lung rates are better characterised because it is possible to estimate clearance from 
cilia motion and has been reported as 5 mm/min with the mucus layer being removed every 
20 minutes [5, 13]. This rate assumes no particles in the mucus and transport rates will 
depend on size of the particle and where it is in the lungs. Five mm/min will only be realistic 
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for the trachea but not the deep airways where the numbers of cilia are reduced [14]. Using 
a stochastically generated asymmetric model of the conducting airways Asgharian et al. [14] 
produced values for the deeper lung structure, with 1.0mm/min at 4 branches and 
0.1mm/min at 8 branches. Therefore drug containing particles delivered to the deep lung 
will remain much longer, up to 24 hours in the peripheral bronchiolar airways [14].  
 
The mucus layer of the eye is the thinnest of all the mucus covered epithelium, being 
between 0.2-1µm [15], consisting of a gel layer on top of membrane bound mucins. The 
turnover of the mucus layer is difficult to measure and values of seconds to hours have been 
quoted [3, 5]. Possibly the most accurate estimates have come from nanoparticle residency 
times on the eye with the assumption that they are binding to the mucus layer. Using this 
data mucus turnover times are around 40 minutes [2]. However some caution is needed is it 
is not always clear if the particles have penetrated into the cells.   
 
Cervico-vaginal mucus is reported to be tens of µm thick and to have a turn over time of a 
few hours [5]. Unlike other mucus gels its physical properties are modulated during the 
menstrual cycle, when it becomes much less viscous during ovulation. This change would be 
expected to increase clearance rates of delivered drugs.  
 
As the number of potential strategies and systems for delivery through mucus increases, the 
safety of these must be considered, in terms of the effect on the mucus layer and the 
underlying mucosa.   
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In this review we consider the safety and efficacy of the available mucus modulating drug 
delivery systems and consider the gaps in our current knowledge.  
 
2. The delivery system? 
2.1. Nanoparticles 
Nanoparticles can be defined as particles with at least one dimension 100nm or less and 
having a high surface to volume ratio [16].  The first consideration is size. Nanoparticles 
have the potential to penetrate the mucus layer if they are below the range of the mucus 
pores ~ 200nm [17]. However surface characteristics may mean they interact with the 
mucus and do not pass through. Several modifications have been applied to nanoparticles 
to enhance their mucus penetrating properties (Table 1). 
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Table 1  Approaches to permeating the mucus layer 
Approaches to permeating the 
mucus layer 
Effective agent Mucus Layer Ref 
Slippery Surface PEG, Methyl silicones Native Healthy 
[18, 
19] 
    
High density charged surface 
with approx. same number of 
+ve and –ve charges to give a 
net charge close to neutral 
Polyacrylic acid/polyallylamine 
Arginine-glutamic acid 
Native Healthy 
[20, 
21] 
    
Neutral to low surface charge 
Poly acrylic acid, chitosan, dextrans, 
cyclodextrans 
Native Healthy [20] 
    
SNEDDS / 
Liposomes 
Hydrophobic surface and small size 
mixture of glycerides, triglycerides 
and surfactants 
Native Healthy 
[22-
25] 
    
Disulphide bond breakers 
released from the nanoparticle 
or used in conjunction with the 
delivery system 
N-acetylcysteine, mercaptobenzoic 
acids, Dithiotheitol 
Native Healthy [26] 
    
Proteolytic (mucolytic) enzymes 
attached to the NP surface 
Papain, trypsin, Bromelain Native Healthy 
[27, 
28] 
    
Thiomers that change reactivity 
depending on pH 
Polyacrylic acid, cysteine conjugates Native Healthy [29] 
    
Nanoparticles with surface 
charge changing characteristics 
Polyacrylic acid, n-acetyl amino acid, 
hydrophobic amino acids side chains 
Native Healthy 
[25, 
30, 
31] 
    
Surface decorated nanoparticles 
with DNase to increase 
permeability 
DNase 
Disease state CF 
mucus 
[32, 
33] 
    
Altering mucus layer 
permeability 
Gelsolin 
Disease state CF 
mucus 
[32] 
    
Agents that regulate mucus 
production and secretion 
Glycopyrrolate, prostaglandin 
synthesis inhibitors 
Healthy and 
Diseased 
[34-
36] 
    
Mucoadhesive particles (1) in 
conjunction with 
Mucopermeating particles (2) 
(1) Amine modified polystyrene 
nanoparticles, (2) PEG coated 
polystyrene particles 
Healthy 
(prolonged 
storage at 4oC) 
[37] 
    
Particles engineered with both 
mucoadhesive and 
mucopermeating properties 
PEG/Chitosan 
Mucus 
suspension 
[38] 
    
Proteolytic enzymes plus a 
disulphide bond breaking agent 
Papain and cysteine  Native healthy [27] 
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2.1.1. A slippery surface 
One way this can be achieved is to coat nanoparticles with polyethylene glycol (PEG). It has 
been demonstrated that non-penetrating, mucoadhesive, particles can be converted to 
mucopenetrating by coating them with short chain PEG between 2,000-5,000 molecular 
weight. Carboxyl modified polystyrene nanoparticles with a surface charge of -33 to -69mV 
did not permeate the mucus layer. However when coated with short chain PEG the charge 
was increased to between -2.2 to -4.0mV they did permeate. When the PEG modified 
nanoparticles were applied to the mucus surface of mice vaginal explants they reached the 
mucosal surface within 10 minutes [18, 19]. It appears that PEG size is critical for this 
enhanced mucus permeating effect, as particles coated with 10,000 molecular weight PEG 
were trapped in the mucus. It has been suggested that the longer chains of PEG can 
penetrate into the hydration sphere of the mucins and form hydrogen bonds [39, 40]. 
 
2.1.2. High density charged surface 
Based on the fact that virus particles, e.g. the Norwalk virus, can rapidly permeate human 
cervical mucus gels [4, 41], nanoparticles have been designed to mimic the virus surface 
characteristics. The Norwalk virus is small, 38nm and has a high surface density of negative 
and positive groups, made up of acidic and basic amino acids. So the surface charge will 
depend on the pH environment. The isoelectric point for this virus is around 4 so it will be 
around neutral at pH between 3-5 [42, 43]. Consequently because cervical mucus has an 
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acidic pH [4] the virus will be near neutral and can pass rapidly through the mucus layer. 
This however may not be the case with a mucus layer with a pH near to 7 where the virus 
would have a negative surface charge. Polyacrylic acid and polyallylamine nanoparticles 
have been produced with an overall surface charge of +0.9mV. These nanoparticles diffused 
around 2x faster than nanoparticles made with polyacrylic acid alone or polyallylamine 
alone in native porcine small intestinal mucus [21]. Abdulkarim et al. [20] produced a series 
of polyacrylic acid (PAA)/chitosan (C) nanoparticles with zeta potentials ranging from -29 to 
+19.5 mV depending on the ratios of PAA:C.  At a ratio of 1:2.2 a near neutral particle with a 
zeta potential of +1.1 ±2.4mV was produced. Its diffusion was measured in porcine small 
intestinal mucus using multiple particle tracking and compared to negative, positive 
nanoparticles, adenovirus AD5 and a PEG-PLGA nanoparticle. In order to account for the 
different sizes of particles their diffusion rates were determined by dividing the diffusion 
coefficient in mucus by the coefficient in water. Based on this ratio the near neutral was 
1.5X faster than the AD5 viral particle (-0.5 ±2.3mV) but the PEG-PLGA (-8.3 ±1.2mV) was 
still 2.6X faster than the near neutral particle. However when compared to the particle 
made from 1:8, PAA:C (+19.2 ±0.6mV) the near neutral particle was 89X faster and 18X 
faster than the particle made from 4:1, PAA:C (-30.6 ±4.4mV). When compared to PLGA 
alone the PEG-PLGA was more than 1000X faster and the near neutral particle was 430X 
faster. The ability of a near neutral particle to permeate mucus effectively relates to lack of 
any charge: charge interaction with the mucins and because these particles have high levels 
of charge there will be reduced hydrophobic interactions with the mucus.  These diffusion 
results indicate the effectiveness of near neutral particles in permeating mucus layers and 
their potential as drug delivery agents.  However, one problem with the near neutral 
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particles is their tendency to form aggregates which means they require sonication before 
use.   
 
2.1.3. Lipid derived delivery systems 
Cationic lipid based liposomes have been produced as their positive charge is useful in 
interacting with a negative DNA cargo in gene delivery and the hydrophobic lipid part can 
interact with the cell membrane enhancing uptake via caveolae and clathrin mediated 
pathways. Efficient transfection can take place if no intact mucus layer is present [23, 44, 
45]. Positively charged liposomes will be strongly adhesive to the mucus layer [20, 44, 45]. 
Neutral liposomes made from cholesterol and phosphatidylcholine again are trapped in the 
mucus layer due to hydrophobic interactions. This can be overcome by coating with PEG 
2000, giving a nanoparticle of 181mn a zeta potential of -13mV, which when loaded with 
interferon alpha gave enhanced delivery of the cargo to an ex vivo sheep vaginal epithelium 
[23]. The size of the liposomes was shown to be important in terms of cellular uptake. A 
study by Li et al. [46] showed that negative liposomes made from phosphatidylcholine and 
medium chain triglycerides (zeta potential ~-50mV) were taken up effectively by Caco-2 
cells. With nanoparticles of 100nm being better than 200nm which were both better than 
300nm. However in the in vivo studies it was not clear if the nanoparticles had passed 
through the mucus layer or been trapped in it. One might expect particles with such a large 
negative charge would be repelled by the mucus layer rather than pass through it. In 
addition both these papers [23, 46] determined nanoparticle interaction with the mucus 
barrier using mucin interaction models with a degraded mucin not representative of the in 
vivo mucus gel [17, 47].   
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A more promising approach using lipids has come with the development of self-
nanoemulsifying drug delivery systems (SNEDDS) which are emulsions of oils and 
surfactants, formed on mixing with water, producing small sizes nanostructures. The sizes 
range from 12-455nm [22, 25]. In the study by Zupancic et al. [25] the size of the SNEDDS 
depended on the lipid component. Long chain lipids (> C10) and medium chain lipids (C8-C10) 
produced droplets of 30-240nm and short chain lipids (< C8) produced droplets of between 
165-265nm. When lipid was excluded from the formulation droplets of 13-68nm were 
produced. 
 
SNEDDS have hydrophobic surface properties which could lead to interaction with 
hydrophobic regions in mucus. As particle size is an important parameter in governing 
mucus permeation [48] and to avoid hydrophobic interactions SNEDDS of small size which 
have space to spare in the mucus pores will permeate the fastest. In addition SNEDDS have 
the ability to deform and change shape to fit through convoluted pores. Consequently 
SNEDDS with short chain lipids were excluded from the mucus diffusion studies. When 
SNEDDS containing long chain (LC) lipids, medium chain (MC) lipids and no lipids (NL), all in 
the size range 30-40nm were compared in their ability to permeate a mucus gel, no lipid and 
medium chain lipid were 2x faster than long chain (LC) lipid SNEDDS. This can be explained 
by the LC SNEDDS having a greater capacity for hydrophobic interactions. This enhanced 
permeation was also exhibited in vivo by MC and NL SNEDDS containing the anticoagulant 
enoxaparin. Experiments in rats showed that enoxaparin could be delivered to the 
circulation orally when contained in MC and NL SNEDDS with an absolute bioavailability of 
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~2% compared to zero for an orally delivered aqueous enoxaparin solution [25]. Another 
positive for the use of SNEDDS as an oral delivery system is their ability to protect the cargo 
from degradative digestive enzymes. SNEDDS (30-40nm) have been developed to 
incorporate insulin as an insulin/dimyristoyl phosphatidylglycerol hydrophobic ion pair and 
have been shown to protect the insulin from proteolytic digestion by the pancreatic 
enzymes trypsin and chymotrypsin [24].   
 
2.1.4. Proteolytic enzyme coating 
Another approach to permeating the mucus barrier is by immobilizing on the surface of 
particles, proteolytic (therefore mucolytic [28]) enzymes e.g. papain. The enzyme is 
attached via covalent interactions between amino groups on the enzyme and carboxyl 
groups on polyacrylic acid using carbodiimide chemistry. Using this technology Muller et al. 
[27] showed that in a transwell system, incorporating porcine small intestinal mucus, that 
papain decorated nanoparticles permeated 3 times faster than the naked polyacrylic acid 
nanoparticles. In addition, if cysteine was added to the particle, papain being a thiol 
dependent enzyme, then the nanoparticles improved their permeation to 3.5 times faster 
than the naked nanoparticle. Demonstrating that these decorated nanoparticles would 
effectively enhance drug delivery.  The authors further showed, in an oral delivery rat study, 
that papain nanoparticles had an increased residency time in the jejunum after 3 hours, 
presumably because they had reached the mucosa under the mucus layer [27]. 
Nanoparticles have been manufactured with other proteolytic enzymes e.g. bromelain and 
trypsin linked to PLGA and these again showed enhanced permeation of porcine small 
intestine mucus, with bromelain being better than trypsin [49]. Most likely due to the 
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enhanced mucolytic activity of bromelain compared to trypsin. In a further study [50] the 
movement of proteolytic enzyme decorated nanoparticles was studied using a rotating tube 
containing porcine small intestinal mucus [51] and the effect on the mucus layer measured 
using pulsed-gradient spin-echo NMR (PGSE-NMR), small angle neutron scattering (SANS) 
and spin-echo SANS (SESANS). Bromelain decorated nanoparticles showed the best 
permeation into the mucus layer with 4.8 times more reaching 6mm into the mucus than 
papain decorated nanoparticles. This was to some extent explained by the fact that 
bromelain survived the production of the enzyme polymer conjugate better and retained 
76% of its enzyme activity compared to 43% for papain. Using a porcine small intestinal 
mucin gel PGSE-NMR demonstrated an increase in mucin diffusion caused by the enzyme 
linked nanoparticles, with bromelain having the biggest effect. These changes were 
confirmed in the porcine small intestinal mucus gel by SANS and SESANS and suggests the 
breakdown of polymeric structure (Figure 1). It is important to note that although bromelain 
linked nanoparticles are better at penetrating mucus the bigger changes in mucus structure 
could compromise its mucosal protection. Consequently these enzyme linked nanoparticles 
should be designed to pass through the mucus layer without too much perturbation of its 
structure. 
 
2.1.5. Reduction of disulphide bridges 
As the gel structure of mucus depends on mucin polymeric structure, agents which reduce 
disulphide bridges such as mercaptoethanol or dithiothreitol have been widely used in 
research and the clinic [52, 53] to dissolve mucus gels by destroying the disulphide based 
mucin polymeric structure. Little research has been carried out to attach –SH containing 
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groups to the outside of drug delivery systems in order to cleave the mucin disulphide 
bridges and completely penetrate the mucus layer. Most research has concentrated on a 
thiomer strategy [29] using the pH gradient in the small intestine, an acid microclimate, pH 
6.0 in the lumen to pH 7.4 close to the epithelial cell surface, which is the same 
microclimate that powers absorption of peptides. The reactive species generated from thiol 
groups is S- (thiolate anion) and it is this that can drive disulphide exchange forming 
disulphide bridges between the nanoparticle and the mucin molecules. The amount of this 
anion depends on the pKa of the thiol ligand e.g. N- acetylcysteine and cysteine have pKa’s 
of 8.2 and 8.4 respectively, meaning that a change in pH from 6 to 7.4 would cause a 
significant increase in disulphide exchange. This would mean that nanoparticles with n-
acetylcysteine of cysteine attached to the surface would not react with the mucin at the 
luminal mucus surface but penetrate close to the cell surface where they would become 
immobilized by interaction with the mucin [54]. Where thiols could increase permeation 
without mucin binding is when nanoparticles have cysteine and papain attached to the 
surface. This combination has been shown to increase their permeation of mucus. This was 
explained by cysteine enhancing the mucolytic activity of papain [27]. However an 
alternative explanation is that cleavage of mucin disulphide bridges could be the reason for 
the enhanced permeation. 
 
2.1.6. Zeta potential changing methodology 
Based on the data showing negatively charged nanoparticles permeated mucus better than 
positively charged ones and positively charged nanoparticles are taken up by cells better 
than negatively charged ones [22, 55] a zeta changing strategy has been developed.  This 
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methodology can be based on the cleavage of a peptide bond by membrane 
endopeptidases. The initial nanoparticles have a negative zeta potential allowing 
permeation of the mucus layer and have conjugated to their surface a peptide containing 
hydrophobic amino acids. When the nanoparticles reach the cell surface the peptide is 
cleaved between hydrophobic amino acids leaving a positively charged amino group 
exposed resulting in a change in zeta potential to positive. Another approach is to link 
glutamic acid to the surface giving a net negative charge and this can be cleaved of at the 
cell surface by γ-glutamyl carbopeptidase resulting in a net positive charge [25]. A third 
approach was developed by Suchaoin et al. [31] and Bonengel et al. [30] where phosphate 
containing polymers were incorporated into nanoparticles to give rise to a negative zeta 
potential. These were converted to a positive zeta potential by the action of intestinal 
alkaline phosphatase. The nanoparticles were self-emulsifying drug delivery systems 
(SEDDS) one with 1, 2 dipalmitoyl-sn-glycero-3-phosphatidic acid containing a terminal 
phosphate group and another with carboxymethyl cellulose/polyethylene imine (PEI) 
nanoparticles with 6 phosphoglucuronic acid (PGA) attached containing a terminal 
phosphate group. Both these nanoparticles could be converted from negative to positive by 
the action of alkaline phosphatase when they were exposed to Caco-2 cells in culture. This 
in vitro culture work suggests that this type of nanoparticle could be effective in vivo but as 
yet there is little in vivo data to confirm this. 
 
2.2. Viral vectors, virus-like particles and nanocages 
These vectors have greater efficacy in terms of gene delivery than conventional 
nanoparticles. Many studies have been carried out in the lung involving gene therapy (see Di 
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Gioia et al. for review [44]). Viral particles can penetrate the mucus layer because of their 
small size e.g. cowpea mosaic virus (CPMV) (31nm), cowpea chlorotic mottle virus (CCMV) 
(18nm) and bacteriophage MS2 (27nm) [56] and near neutral surface charge. They do not 
cause changes to the mucus layer as they pass through it but when they reach the target 
cells can induce strong immune responses including cytokine release from the epithelial 
cells. Toxicology studies in mice demonstrated that CCMV produced a large IgM and IgG 
response and CPMV showed a general increase in the immune response [57, 58]. Cytokine 
release will stimulate mucus secretion increasing the mucus barrier thickness; slowing the 
rate of cargo delivery from subsequent dosing [59]. In general nanoparticles are safer than 
viral vectors.  Nanocages based on ferritin (an iron transport protein which would not 
promote an immune response in humans) can be formed with a central space which can be 
loaded with an API [60].  It can then be surface coated with PEG to allow penetration 
through the mucus layer in vivo. The added value of the ferritin presence in the nanoparticle 
is that its receptor is highly expressed in many tumour cells [61].  So Any API should be 
selectively taken up by cancer cells.  Huang et al. [62] loaded the cages with doxorubicin and 
delivered these to the lung by intranasal instillation.  The doxorubicin loaded nanocages 
improved survival compared to doxorubicin solution alone in a mouse lung cancer model.   
2.3. Combinations of drug delivery strategies 
Wang et al. [37] investigated a two particle strategy, a mucoadhesive particle to interact 
with the mucins in the mucus gel leading to an enlargement of the pores in the gel.  The 
formulation could then contain a mucopermeating particle which would pass unhindered 
through these enlarged pores.  Another two strategy approach was adopted by Sharma et al 
[38] using PEG conjugated chitosan nanoparticles loaded with soluble telmisartan, an 
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angiotensin II receptor blocker.  This gave a balance between mucoadhesion by chitosan 
and the mucopenetrative properties of PEG, in the hope of retaining the nanoparticles in 
the deeper layers of the mucus and closer to the epithelium.   
 
Another potential dual strategy is where nanoparticles decorated with papain can permeate 
the mucus layer faster when cysteine is present.  This was explained by the authors as 
cysteine activation of the enzyme [27].  An alternative explanation is that permeation was 
enhanced due to the disruption of mucin-mucin disulphide bridges by the action of the thiol 
containing amino acid. 
3. What about the mucus layer, how can it be modulated? 
3.1. Mucolytic agents added prior to or with the delivery system 
Mucolytic agents such as N-acetylcysteine (NAC) have been used to enhance drug delivery in 
the intestine. Takatsuka et al. [26] demonstrated that treatment of exteriorised rat jejunum 
with 5% NAC and 5% non-ionic surfactant enhanced the uptake of calcitonin. However, this 
lead to acute mucosal damage as demonstrated by necrotic villi and shortening of villus 
height. This damage was reversible within 2 hours post administration. However, even short 
time exposure of the mucosa could allow pathogen access [63]. This approach has problems 
as the rats were fasted and the jejunum exteriorised, incised, and solutions were 
administered through an adhered delivery device. Consequently the mucosa was not 
exposed to the normal range of gastric and pancreatic digestive fluids which could lead to 
much more damage. It is therefore very important to consider digestive fluids in any 
damage model. 
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Broughton-Head et al. [32] have considered the use of “mucolytic agents” in enhancing drug 
delivery through a diseased mucus layer. In cystic fibrosis (CF) the airway mucus layer is 
dehydrated and thickened due to inflammatory responses to pathogenic infections and 
contains larger quantities of DNA and actin [64, 65]. Consequently agents that act on all the 
biopolymers present including mucin could enhance drug delivery either to the mucosa or 
to bacterial colonies within the mucus. The study [32] used combinations of these 
biopolymers to generate CF mucus like material and measured the diffusion of 200nm 
fluorescent carboxylated nanospheres. As expected mixtures of mucin and DNA retarded 
the diffusion of the nanospheres compared to a PBS control and the diffusion rates returned 
to control levels with DNase or NAC treatment. Addition of F-actin did not retard the 
nanospheres any more than DNA and mucin mixtures. It did however inhibit the ability of 
DNase or NAC to enhance the diffusion. Depolymerising the actin with gelsolin did not 
correct this inhibition. This implies that the presence of actin in any state of polymerisation 
can inhibit the ability of conventional agents used as mucolytics in CF to enhance 
penetration into the mucus layer. Some caution must be applied when extrapolating this 
data to the CF lung as the mucin used was a commercial preparation which does not have 
the gel forming properties of native mucus [17]. This may explain why the mixture of actin, 
mucin and DNA at the concentrations found in CF airway mucus did not retard diffusion of 
nanospheres as much as CF sputum, 53% and 96% respectively [32]. The need to deliver 
antibiotics effectively in cystic fibrosis has led to attempts to improve antibiotic delivery to a 
key bacterium, Pseudomonas aeruginosa [66]. To achieve this they linked DNase to the 
outside of nanoparticles containing tobramycin an antibiotic effective against Pseudomonas 
[33]. The authors generated a model of nanoparticle penetration by overlaying a gelatin 
layer with cystic fibrosis sputum and applying fluorescently labelled nanoparticles to the 
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sputum surface. After 24 hours the fluorescence levels in the gelatin were measured and 
equated to the percentage of nanoparticles had permeated the sputum. Tobramycin has 
serious dose related side effects, e.g. nephrotoxicity and ototoxicity [67] and a narrow 
therapeutic index. 
Consequently a great treatment advance could be achieved if it could be packaged in 
nanoparticles that could penetrate the mucus to the site of the infection and release the 
antibiotic, generating high local concentrations with antimicrobial effects and greatly 
reduced systemic effects. The study showed that alginate-tobramycin complexes could be 
successfully formed into nanoparticles with chitosan and surface coated with DNase linked 
via a carbodiimide reaction and could successfully penetrate cystic fibrosis mucus and kill 
Pseudomonas colonies within the mucus.  
 
3.2. Agents that regulate mucus production and secretion 
 
Drugs such as glycopyrrolate block parasympathetic nerve activity which normally 
stimulates mucus secretion in the airways. Glycopyrrolate and similar drugs may be useful 
when the mucus layer is thickened by disease related hypersecretion [68] but may expose 
the mucosa to potential insult in the normal situation. It is well documented that 
prostaglandins stimulate the production of normal mucus levels in the gastrointestinal tract 
[35, 36]. Inhibition of prostaglandin synthesis by compounds such as non-steroidal anti-
inflammatory drugs (e.g. indomethacin) and by glucocorticoids [34] could be used to 
compromise the mucus layer to allow effective drug access to the mucosa. However this 
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could only be attempted in the acute situation as long term prostaglandin inhibition leads to 
gastric damage.   
4. Mucus Models 
4.1. Modelling GI delivery of Drug Delivery Systems 
Robust in vitro models can provide useful tools for assessing safety and efficacy which can 
complement, reduce and occasionally replace in vivo models, however aiming to accurately 
simulate the passage of delivery formulations through the gastrointestinal tract in vitro 
carries a number of challenges. 
 
In oral delivery of particle formulations, there are three ‘barriers’ which must be considered; 
the digestive barrier, the mucus barrier and the epithelial barrier.  
 
Methods exist to model the digestive, mucus permeation and epithelial phases in isolation 
however there are a number of challenges to integrate modelling of these phases into a 
single system. Small intestinal fluids contain proteases and components of bile which are 
toxic to cells. The normal function of mucus in vivo protects the underlying epithelia from 
damage by these digestive fluids, however replicating this effect in vitro has proved 
challenging.  
Due to ease of use, cost, reproducibility and positive correlations with in vivo data, Caco-2 
cell lines have become the most widely accepted model for in vitro modelling of small 
intestinal permeability [69]. Caco-2 cells are highly differentiated with appropriate 
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morphology, brush border enzyme expression, tight junctions and can be used to model 
active and passive transport as well as efflux [69]. However Caco-2 monocultures produce 
no significant mucus layer and so cannot be combined with simulated digestive fluids. 
Appropriate composition of digestive fluids has been discussed in Minekus et al. [70].  
Furthermore, the mucus barrier in vivo may keep delivery systems from direct contact with 
the epithelia, while allowing them in close enough proximity to deliver their payload. In 
direct application of the delivery systems to a cell-culture system, this protective barrier 
effect would not be replicated, and cytotoxic effects of delivery systems such as those 
decorated with proteases may be overestimated.  
Incorporation of a mucus barrier is of ‘key importance’ to evaluating mucosal drug 
permeation [71]. Caco-2/HT29-MTX co-cultures have been adopted to overcome the lack of 
a mucus layer. However the mucus layer produced with Caco-2/HT29MTX co-culture is 2-
10μm thick, as compared to an in vivo thickness of up to 400-500μm [72]. This means that 
even co-culture systems cannot be integrated with whole digestive fluids due to cell death. 
Some gastrointestinal models, such as the TIM model designed by Minekus et al.,[73] aim to 
mimic the absorptive phase through dialysis across a semi-permeable membrane to 
simulate small intestinal uptake. The authors argue that this ‘closely approximates 
absorption of nutrients through the lumen of the gut’; although it is understood elsewhere 
that intestinal absorption is somewhat more complex than size exclusion diffusion.  
Methods have been developed to test the permeation of nanoparticle delivery systems such 
as SNEDDS through an intestinal mucus layer in a transwell set-up [74]. However, while 
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providing a useful model of mucus permeation, the non-sterile native mucus used in these 
systems would not be compatible with a cell culture system [71].  
Attempts have been made to use ‘biosimilar’ mucus which can be combined with cell 
culture systems without causing cell death. Boegh et al. [71] showed that porcine intestinal 
mucus disrupted a Caco-2 monolayer, and therefore adopted a ‘biosimilar’ mucus 
composed of degraded gastric commercial mucin, bovine serum albumin, cholesterol, 
phosphatidylcholine, linoleic acid and the non-natural component polyacrylic acid, which 
was responsible for steric barrier properties in the model. However, in their own research, 
significant differences in peptide permeability were shown between porcine intestinal 
mucus and biosimilar mucus.  
Methods such as the M-SHIME large intestinal model from ProDigest have adopted a 
compartmentalised approach to work around the problems of integrating a mucus layer 
with a cell culture system. In this model, an enterocyte monolayer is grown in the lower 
compartment, and in the upper compartment, an artificial mucus layer is applied to a semi-
permeable membrane. This means bacteria can be grown in the ‘luminal’ chamber, and the 
products of both the epithelial and bacterial cultures can freely diffuse across the semi-
permeable membrane without the artificial mucus or luminal contents coming into direct 
contact with the enterocyte culture. Furthermore the artificial mucus used in this system is 
a mucin-agar mix (Figure 2).  
We were only able to find limited information about the methodology, however, in Abeele 
et al. [75] and Marzorati et al. [76], Sigma-Aldrich porcine gastric mucin type II was mixed 
5% (w/v) with agar and sterilised by autoclaving at 121°C. The limitations of Sigma-Aldrich 
mucin, and other commercially available mucins have been discussed elsewhere, as the 
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action of proteases during the isolation process damages mucin structure and effects mucin-
mucin interaction, destroying their ability to form gels [77].  We were unable to find 
literature regarding the effects of autoclaving on mucin; we are tempted to speculate that 
no one has felt these experiments were necessary to show the effects on mucin structure 
would be catastrophic.  
 
 
Figure 2  Adapted from Marzorati et al. [78]. Schematic diagram of an ‘adhesion unit’ 
for the study of study of microbial growth and host-microbiota interaction. The functional 
‘mucus’ layer consists of a layer of agar-mucin mix which has undergone autoclaving, which 
is separated from an epithelial culture in the basal chamber by a semi-permeable 
membrane. The luminal chamber is supplied with continuous flow to/from the SHIME 
model.  
 
Unpublished work in our lab has made significant progress in combining a purified and 
rebuilt mucus layer directly with cell-culture systems without compromising cell viability (at 
5 hours). Furthermore this mucus layer contains no artificial components and can afford 
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protection from whole digestive fluids complete with bile, proteases, carbohydratases and 
lipases.  
 
A number of model gut systems have been developed to study different aspects of digestion 
and GI physiology. These include; bioavailability and bioaccessibility of contaminants [79], 
digestion of allergens [80] study of pre and probiotics [81], models of gut motility, peristaltic 
motion and physiological mixing and shearing [82], enzymatic digestion[82], substrate 
digestion and interaction [83], intestinal microbiota [84], water and nutrient absorption [85] 
and drug delivery [86]. 
Wickham et al. 2009, define the three stages of digestion which upper GI models must 
consider; “(i) processing in the mouth, (ii) processing in the stomach (cumulative to the 
mouth) and (iii) processing in the duodenum (cumulative of the mouth and stomach)” [87]. 
Blanquet et al. 2004, define the importance of accurate modelling of the physiological 
composition of the digestive fluids, and accurate simulation of the physical forces and 
uptake processes which digesta is subject to; “(i) sequential use of enzymes in physiological 
amounts, (ii) appropriate pH for the enzymes and addition of relevant cofactors such as bile 
salts and coenzymes, (iii) removal of the products of digestion, (iv) appropriate mixing at 
each stage of digestion, and (v) physiological transit times for each step of digestion.” [88].   
To add to these definitions we would argue that a robust in vitro model for testing oral drug 
delivery of nanoparticles, as well as meeting the above criteria for the digestive phase 
should also include a non-artificial mucus layer which retains the rheological properties of 
native mucus, applied directly to a representative cell culture system.  
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5. Safety concerns of mucus modulating delivery systems/agents 
In order to effectively penetrate the mucus barrier nanoparticles have been surface coated 
to give near neutral/negative zeta potentials and as such are less cytotoxic to non-
phagocytic cells such as absorptive mucosa but are more cytotoxic to phagocytic cells than 
positively charged nanoparticles [89]. 
 
PEG coating can make positive particles neutral on the surface and thereby enhance mucus 
permeation. PEG coating of positively charged nanoparticles also reduces cytotoxicity as 
shown with human cervix epithelial carcinoma cells [90]. Extensive safety testing in animals 
has demonstrated LD50 values of 2g/Kg for PEG delivered via an oral route and no evidence 
of genotoxicity or carcinogenicity [91]. 
 
Poly anhydride nanoparticles have been developed for drug delivery in several bacterial 
diseases and in targeted delivery in cancer [92-94] but are adaptable for oral delivery in 
many diseases. They can be designed for oral delivery with reduced toxicity of the payload 
drug and can be surface modified to enhance mucus permeation. They have the further 
advantage of being biodegradable with low levels of toxicity [95]. Iglesias et al. [96] 
demonstrated that poly anhydride nanoparticle surface modified with PEG , mannosamine, 
2-hydroxypropyl –β-cyclodextran, dextran or aminodextran producing a negative zeta 
potential demonstrated enhanced mucus permeation. In addition they had low toxicity with 
concentrations up to 10mg/ml with Caco-2 cells, detected using ATP and membrane 
integrity assays. Concentrations of 2 mg/ml showed no effect on cell proliferation or DNA 
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damage (genotoxicity) using an alkaline comet assay in combination with the enzyme 
formamidopyrimidine DNA-glycosylase [97]. 
 
PLGA nanoparticles are biodegradable and show low cytotoxicity even up to 300mg/ml [98] 
with a macrophage and an epithelial cell line. However at 300mg/ml there was a 3 fold 
increase in the levels of the inflammatory cytokine inflammation TNFα. This was size 
dependent with small particles being more inflammatory due to the binding protein. PLGA 
nanoparticles can be made more negative by the addition of poloxamer for example but this 
can also increase cytotoxicity as shown with Calu-3 lung epithelial cells. This effect appears 
to be due to the poloxamer directly [99]. 
 
As all absorptive mucosa contain immune cells such as phagocytic macrophages which are 
important in preventing microbial invasion.  Penetrating to the mucosa with negatively 
charged nanoparticles could compromise mucosal protection as they are cytotoxic to 
macrophages. 
 
A two particle strategy was proposed by Wang et al. [37] with high concentrations of 
particles that strongly adhered to mucus and opened out the pores in the mucus layer, 
increasing the permeation of a PEG coated nanoparticle. The potential danger of this 
approach is that it may increase microbial access to the mucosa through these enlarged 
pores. 
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Two delivery systems have been combined by Hetenyi et al. [29] (SEDDS and thiomers), in 
this case a thiolated amphiphilic polymer. This combination was seen to improve 
permeation and increased residency time on/or close to the mucosa. However based on 
cytotoxicity studies with Caco-2 cells this delivery system showed significant cell death at 
high concentrations i.e. a 1:100 dilution. Although the concentrations in the lumen of the 
digestive system from oral delivery would be below this level it is not known if these toxic 
concentrations could arise locally at the mucosal surface in vivo. 
 
Another mucus permeating method is zeta potential changing systems. However, the 
cytotoxicity of the surface entities that are modified by enzymatic action need to be 
carefully assed. For example PEI-6PGA covered carboxymethyl cellulose particles at 1mg/ml 
caused ~70% cell death of Caco-2 cells and the surface components PEI almost 100% and 
6PGA~70% at equivalent concentrations [30]. 
 
SEDDS have also been modified with 1, 2 dipalmitoyl-sn-glycero-3-phosphatidic acid to 
generate a zeta potential changing system. Again high concentrations of these SEDDS at a 
dilution of 1:100 led to an 80% loss of Caco-2 cell viability [31]. 
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In addition the composition of the SEDDS can make them more or less toxic. Karamanidou et 
al. [24] showed that using lauroglycol FCC in their SEDDS led to a reduction in safe 
concentration from 2mg/ml to 0.25mg/ml. 
 
A note of caution should be applied to cytotoxicity measurements when selecting drug 
delivery systems as safe to proceed to animal studies and clinical trials. The most commonly 
used cytotoxicity test involves MTT (tetrazolium dye assay) [100] and modifications of this 
assay which measure mitochondrial function via the activity of mitochondrial enzymes 
which produces a coloured product. The cells used are transformed cell lines which are 
more resistant to toxic agents than primary cells which more closely resemble in vivo.  It has 
been shown that there are several ways the delivery system can interfere with the assay: 1. 
giving a background absorbance; 2. binding to the coloured product; 3. having surface 
oxidative properties [101]. 
 
A key property of a mucus modulating drug delivery system is that the mucus layer retains 
its protective function after penetration. Wilcox et al. [102] demonstrated that 
nanoparticles decorated with proteolytic enzymes could penetrate small intestine mucus 
without altering its global rheological properties. The properties of mucus being able to flow 
and reanneal when ruptured [103] would mean that the pores produced by the proteolytic 
enzymes would seal relatively quickly. This would not be the case with total removal of the 
layer with free proteolytic enzymes or reducing agents like NAC, where the mucosa would 
remain unprotected until a new layer is secreted. Another potentially detrimental situation 
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is the opening up of pores with mucoadhesive particles [37] as this will prevent the ability of 
the mucus to flow and refill the enlarged pores. 
6. Conclusions and future perspectives 
There are many new developments in drug delivery systems targeted to overcome the 
mucus barrier which covers most potential drug delivery sites and most have shown 
enhanced permeation of mucus.  The problem is that most of the new formulations will 
require extensive safety and clinical trials before they could be used in the clinic.  In general 
there is a lack of toxicological data in primary epithelial cell and this must be addressed.   
A further large gap in our understanding is the turnover rates for mucus in vivo which can 
potentially vary at different sites within the same organ.  Also mucus turnover in the GI tract 
will vary on the fed vs fasting situation.  The presence of food will increase the shear on the 
surface of the mucus layer, some of which will mix with the food bolus to lubricate its 
passage through the gut.  In addition there is little or no data on the differential turnover of 
the shear compliant and the shear non-compliant mucus layers.  This needs to be 
determined so that accurate modelling can be made of drug delivery system transit rates.   
Finally it is imperative to develop physiologically relevant in vitro systems that reliably 
model the supra-mucus barriers, mucus and cell barriers to delivery.   
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